Disparities of Care in ROP

Show Description +

Is a premature infant's birthplace a determinant of whether that infant will receive timely treatment for retinopathy of prematurity (ROP)? Maria Berrocal, MD, speaks with Yoshi Yonekawa, MD, corresponding author on a study mapping geographic and socioeconomic disparities in access to ROP treatment across the United States. The study analyzed driving times and distances from census tracts to NICU-based treatment centers nationwide. Watch this interview to learn which geographic factors were linked with reduced access to care.

Posted: 11/02/2026

Up Next

Can Metformin Use Cut Wet AMD Risk?

Maria Berrocal, MD and Dimitra Skondra, MD, PhD


Vitreous Sensing Vitrectomy

Maria Berrocal, MD and Jordan Deaner, MD

New Methotrexate Protocol in RD Repair in High-Risk PVR Cases

Maria Berrocal, MD and Maggie Runner, MD

Trends in PDR Treatments

Maria Berrocal, MD; and Katherine Talcott, MD

MH Risk Factors After RRD Repair

Maria Berrocal, MD and Avni Finn, MD

Anti-VEGF for Proliferative Sickle Cell Retinopathy

Maria Berrocal, MD and Jennifer Lim, MD

Can LLMs Conduct Human-level Research?

Maria Berrocal, MD; Ariel Ong, MD; and David Merle, MD

ILM Peeling for Small Macular Hole

Maria Berrocal, MD and Francesco Boscia, MD

RRDs After Macular Surgery

Maria Berrocal, MD and J. Fernando Arevalo, MD, PhD

AI for Ocular Oncology

Maria Berrocal, MD and Zelia Correa, MD, PhD

TKIs and the Future of Care

Maria Berrocal, MD and Dilsher Dhoot, MD

Growing Comfortable with the Suprachoroidal Space

Maria Berrocal, MD, and Robert L. Avery, MD

Update on Predatory "Cell Therapy" Clinics

María H. Berrocal, MD and Ajay Kuriyan, MD

Is Teleretinal Screening for DR and DME Effective?

María H. Berrocal, MD; and Christina Y. Weng, MD, MBA

Clinical Minute: Retina: Features Associated with Progression to GA in AMD

Maria Berrocal, MD, and Usha Chakravarthy, MD, PhD

Clinical Minute: Retina: Simultaneous UWF Imaging with OCT and FFA/ICGA

Paulo E. Stanga, MD, and Maria H. Berrocal, MD

Clinical Minute: Retina: AI in ROP

María Berrocal, MD and Darius Moshfeghi, MD

Clinical Minute: Retina: The Mac Tel Project

María Berrocal, MD and Lihteh Wu, MD

Clinical Minute: Retina: The Future of the PDS with Ranibizumab

Dante Pieramici, MD and María Berrocal, MD

Clinical Minute Retina: PPV for VH Secondary to RVO

Ramin Tadayoni, MD, PhD and Carl Regillo, MD

GATHER2 Data at 1 and 2 Years

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Biosimilars in Retina

Ramin Tadayoni, MD, PhD, and Prof. Frank Holz

Meta-analysis of Anti-VEGF Agents in Wet AMD Therapy

Ramin Tadayoni, MD, PhD and Jean-Francois Korobelnik, MD, PhD

PPV vs Conventional Therapy for PDR

María H. Berrocal, MD, and Ramin Tadayoni, MD, PhD

GA Therapy After the Newest DERBY/OAKS Data

Eleonora Lad, MD, PhD and Ramin Tadayoni, MD, PhD

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

TRUCKEE Study Data

Ramin Tadayoni, MD, PhD and Arshad Khanani, MD, MA

Pegcetacoplan Phase 3 Data

Ramin Tadayoni, MD, PhD and Caroline Baumal, MD

Rates of Endophthalmitis in a Nationwide Study

Ramin Tadayoni, MD, PhD; and Catherine Creuzot-Garcher, MD

Why Some Clinical Trials Succeed Where Others Do Not

Ramin Tadayoni, MD, PhD; and Peter Kaiser, MD

AI in Retinal Imaging

Ramin Tadayoni, MD, PhD; Ursula Schmidt-Erfurth, MD

Intraoperative OCT: From Concept to Execution

Ramin Tadayoni, MD, PhD; and Cynthia Toth, MD

AI in the Modern Age of Retina

Anat Loewenstein MD, MHA

The History of ILM Staining

Ramin Tadayoni MD, PhD; and Kazuaki Kadonosono, MD, PhD

Phase 3 Faricimab Data and the Dawn of a New Molecule

Ramin Tadayoni, MD, PhD and Charles Wykoff, MD, PhD

Disparities of Care in ROP

Is a premature infant's birthplace a determinant of whether that infant will receive timely treatment for retinopathy of prematurity (ROP)? Maria Berrocal, MD, speaks with Yoshi Yonekawa, MD, corresponding author on a study mapping geographic and socioeconomic disparities in access to ROP treatment across the United States. The study analyzed driving times and distances from census tracts to NICU-based treatment centers nationwide. Watch this interview to learn which geographic factors were linked with reduced access to care.

Posted: 11/02/2026

Read Transcript

Maria Berrocal: Hello, and welcome to Clinical Minute. I'm your host, Maria Berrocal. Each episode highlights research that can refine how we care for our patients. Today, I'm joined by Dr. Yoshihiro Yonekawa, corresponding author on a recent paper examining geographic and socioeconomic disparities in ROP. Dr. Yonekawa, thank you so much for joining me.

Yoshihiro Yonekawa: Dr. Berrocal, thanks so much for having me. It's a pleasure.

Maria Berrocal: Yes, this is a very important topic. So can you please summarize your findings in the paper?

Yoshihiro Yonekawa: Sure thing. So first of all, I just want to give a lot of credit to our fellow at the time who spearheaded this project. Her name is Rebecca Soares, who should be the one sitting here. She's not at the meeting this year, but she put amazing work into this.

And so, in ROP care, we've been talking about difficulties with access to care, access to ROP treatment in the United States. We've been talking about this for decades, and we know that there's a problem, but there was never objective data showing this. Before this, it was a PAT survey from, like, 15 or 20 years ago now, showing that fewer people are interested in doing ROP care. But other than that, there's nothing.

And so what we did was use a data set that was available of NICUs and whether they do ROP treatment or not. We mapped it out throughout the country, and we measured driving times and distances from census tracts to these ROP care treatment centers.

We found a couple of findings. One, as expected, there was less access to care if you lived in a rural area compared to urban or suburban areas. Areas with higher rates of poverty, less education, and non-white populations were at the highest risk for decreased access to care.

Maria Berrocal: Okay. And how do you think policy can be changed to address this significant problem?

Yoshihiro Yonekawa: Yeah. So we do studies because we want to improve care, right? But I think the first thing to do is to show that there's a problem, because before now, we didn't have data to bring to policymakers to show that there's a problem.

And so I think this is kind of the first step in identifying the problem that there are disparities in access. And we did show that poverty had, I think, one of the highest odds ratios.

And for that, the reason we think is: If you're in poverty, you have less prenatal care. If you have less prenatal care, you have more premature births. More premature births, you get ROP.

And so I think that's where resources can be shifted. It really makes us double down on the importance of prenatal care. That's one.

Maria Berrocal: And did you see any disparities in different regions in the United States?

Yoshihiro Yonekawa: Yeah, great point. So the U.S. is so big, and living in the Northeast, everything is clustered together. So, as you can imagine, living in the Northeast, you had very few access-to-care issues. If you lived in the West or the South, you were at higher risk for decreased care.

Maria Berrocal: Okay. So those are the areas where maybe governments, you know, and state governments can put more effort into this.

So how do you think technology could be used to address these disparities?

Yoshihiro Yonekawa: Yeah, you know, we talk about technology and ROP a lot, but the vast majority of the conversation is in screening.

So we have telemedicine, which has been game changing for access to screening for ROP, but the cameras can't do injections. The cameras can't do lasers. You know, it'll be the day when the machines take over, basically. But until the cameras can do that, we still need physicians to provide the care.

And in rural America, there are fewer NICUs, but also fewer treaters. And so I think that's an area that we need to work on.

But with the advent of anti-VEGF agents, I think that has probably increased the workforce because it's easier to do injections than lasers. So more people are able to provide that care.

So I think that's been another element that we don't talk enough about that's been kind of game changing in terms of access.


Please log in to leave a comment.